Company Description
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally.
The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services.
In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community.
Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets.
OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
| Country | United States |
| Founded | 2000 |
| IPO Date | Nov 12, 1986 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 638 |
| CEO | Ms. Carrie Eglinton Manner |
Contact Details
Address: 220 E First St Bethlehem, Pennsylvania 18015 United States | |
| Phone | (503) 641-6115 |
| Website | orasure.com |
Stock Details
| Ticker Symbol | OSUR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001116463 |
| CUSIP Number | 68554V108 |
| ISIN Number | US68554V1089 |
| Employer ID | 36-4370966 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Carrie Eglinton Manner | President, Chief Executive Officer and Director |
| Kenneth J. McGrath | Chief Financial Officer |
| Kathleen Gallagher Weber | Chief Product Officer |
| Michele Anthony | Senior Vice President, Chief Accounting Officer, Controller and Assistant Secretary |
| Rafal Iwasiow Ph.D. | Vice President of Science, Innovation and Technology |
| Jason Michael Plagman | Vice President of Investor Relations |
| Stefano Taucer | General Counsel and Corporate Secretary |
| David A. Rappaport C.F.A. | Senior Vice President Corporate Development, Strategy and Integration |
| Amy Steigerwalt | Senior Vice President of Human Resources |
| Zachary Wert | Senior Vice President of Global Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | 8-K | Current Report |
| Apr 4, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 4, 2024 | ARS | Filing |
| Apr 3, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 22, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 11, 2024 | 10-K | Annual Report |
| Feb 27, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |